ABSTRACT
INTRODUCTION
The survival rate of young patients with cancer has greatly improved in the past decades, in part due to the introduction of new therapeutic agents and protocols 1, 2 . As treatment improves, the number of cancer survivors desiring children increases, thus arousing worldwide interest in fertility preservation 3, 4 . Unlike in the thymus, gastrointestinal tract and bone marrow, damage induced by chemotherapy in the ovary is progressive and irreversible, since the woman's germ cell pool is limited and defined in intrauterine life. This effect is variable, ranging from transient to permanent amenorrhea, infertility or early menopause 5 . Moreover, it depends on the chemotherapy regimen used, the woman's age and the previous ovarian reserve 5, 6 . The cytotoxic effect of alkylating agents is greater in dividing cells such as ovarian cells. Thus, it is believed that keeping these cells at rest through hypothalamic-pituitary-gonadal axis inhibition decreases their susceptibility to the deleterious effects of chemotherapy. In accordance with this hypothesis, the protective effect of gonadotropin-releasing hormone agonist (GnRHa) on the gonads started to be tested in animals, such as rats and monkeys, treated with cyclophosphamide, with some promising results 7, 8 . Phase-II studies, for the most part, also showed the benefit of this intervention in women with breast cancer or lymphoma. However, Phase-III studies have shown conflicting results and many of them were not controlled or randomized. Others did not use samples large enough to evaluate the difference between treatments with sufficient statistical power 9, 10 . Despite numerous attempts to synthesize the results in several meta-analyses [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , the subject remains controversial. This systematic review and meta-analysis was designed to evaluate the efficacy of GnRHa in ovarian reserve protection before and during cancer chemotherapy in premenopausal women without previous diagnosis of infertility. In addition to incorporating new data published in the past 2 years, we aimed at identifying neglected methodological aspects that have compromised the quality of the available studies and how these could be resolved in future investigations. 21 .
METHODS

This systematic review and meta-analysis was conducted following the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions
Eligibility criteria
We considered eligible only randomized controlled trials (RCTs) comparing the effect of GnRHa (regardless of type, dose and route of administration) before and/or during chemotherapy vs chemotherapy plus placebo or vs chemotherapy alone. Participants had to be premenopausal women without a history of infertility and with a recent diagnosis of any type or stage of cancer, except those treated with ovarian surgery or pelvic irradiation. Primary outcome measure was the rate of primary ovarian insufficiency (POI) and secondary outcome was the rate of spontaneous pregnancy at follow-up, after completion of the treatment. Spanish, Portuguese, Italian or French). A manual search of references of the included studies and reviews available on the subject was also conducted.
Literature search
Data collection and analysis
Two reviewers (J.C.S. and F.M.R.) read independently the titles and abstracts of the papers found by the predefined search strategy and applied the inclusion criteria. Then, the remaining studies or those without abstracts were obtained in full version and, again, read independently, intending to evaluate the same eligibility criteria. Any conflicts were resolved by consensus after discussion with a third reviewer (R.L.C.T.). The same two reviewers independently extracted data from the selected studies, such as information about the setting, publication date, study design, number and characteristics of participants, interventions, outcomes, definition of POI, follow-up duration and potential sources of bias. Disagreements were resolved by joint discussion between the two reviewers.
The risk of bias of each study was assessed according to the Cochrane Handbook 21 and computed for seven domains as low, unclear or high ( Figure S1 ). The overall risk of bias of each study was considered low if all domains were classified as low risk, high if at least one domain was classified as high risk and unclear otherwise 21 . The quality of evidence regarding each outcome was evaluated according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, which considers the study design, limitations (risk of bias), imprecision, inconsistency, indirectness and magnitude of effect 22 . The quality of the evidence was classified as high when further studies are unlikely to change the current results, moderate when further studies can change the results, low when further studies are very likely to impact the results and very low when the results are very uncertain 22 . Data were analyzed using Review Manager (RevMan) version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Dichotomous outcomes were compared using relative risk (RR) with 95% CI, using the Mantel-Haenszel statistical test. The random effects model was chosen because we decided not to assume that all studies would share a common effect size and direction 21 . Heterogeneity was judged statistically significant if I 2 was higher than 50% in the total analysis.
Subgroup analyses were performed evaluating the type of disease, the hormonal receptor status of breast cancer and the toxicity of the chemotherapy regimen used. Breast cancer patients who used cyclophosphamide, fluorouracil and a third agent and lymphoma patients treated with alkylating agents were classified as having received highly gonadotoxic chemotherapy 6 . Sensitivity analysis was also conducted to verify the effect of individual studies on the pooled results, by exclusion of each included study, separately, with new statistical analysis of the remaining ones.
RESULTS
A total of 673 articles were identified, of which 670 were found by searching electronic databases (PubMed, 306; LILACS, 301; CENTRAL, 44; Clinicaltrials.gov, 19) and three by manual search. After exclusion of duplicates and articles that did not meet the eligibility criteria, by review of titles and abstracts, 24 articles remained, which were evaluated in full. Of these, 11 were excluded for several reasons and the remaining 13 RCTs were included in the meta-analysis (Figure 1 ).
Included studies
Characteristics of participants
A total of 1208 patients were included in the meta-analysis, of whom 609 received some type of GnRHa before and/or during chemotherapy and 599 patients received chemotherapy alone. Patient age ranged from 18 to 53 years and the median age of participants varied between studies from 24 to 45 years. Three studies included 109 patients with lymphoma, of which two studies involved only Hodgkin's lymphoma and one both Hodgkin's and non-Hodgkin's lymphoma, and 10 studies included 1099 patients with breast cancer. Breast cancer stage ranged from I to III and various chemotherapy agents, courses and cumulative doses were used on an individualized basis (Table S1 ). 
Intervention
Five studies involved administration of triptorelin intramuscularly [23] [24] [25] [26] 35 , one used intranasal buserelin 27 , five used goserelin [28] [29] [30] [31] [32] , one administered diphereline 33 and one used leuprolide acetate 34 . In all included studies GnRHa administration was maintained throughout the chemotherapy treatment.
Outcome
Nine studies defined as primary outcome the resumption of menses, which is a surrogate for preserved ovarian function [23] [24] [25] [26] [27] 29, 30, 32, 33 . From these studies we extracted the number of participants that had not resumed menses (i.e. the rate of persistent amenorrhea) at the end of their follow-up. Four studies reported the frequency of POI, defined by persistent amenorrhea and elevated follicle-stimulating hormone (FSH) levels 28, 31, 34, 35 . The duration of follow-up ranged from 6 months 33 to 7 years 25 . As secondary outcome, nine studies reported the number of participants that became pregnant during the follow-up [23] [24] [25] [26] [27] [29] [30] [31] 35 . All reported pregnancies resulted from spontaneous (i.e. not medically assisted) conception. Most studies also measured serum levels of gonadotropins and/or ovarian hormones (Table S1 ) and two studies reported antral follicle counting by ultrasound 24, 29 , but the methods were too diverse to allow for the results to be pooled.
Excluded studies
Most studies that were observational, non-randomized or in which oral contraceptives were used were excluded at the abstract screening phase (Figure 1 ). Of the 11 articles that were excluded after full-text review, two were retrospective studies 36, 37 , two were registered but not completed (NCT02483767 and NCT02430103), one included oral contraceptives in the control group 38 , one was not randomized 39 , two recruited historical controls 40, 41 , one did not include controls 42 and two presented partial results of studies published later in complete version 43, 44 .
Summary of results
The risk of POI (or amenorrhea) was reduced in women receiving GnRHa plus chemotherapy (119/609) compared with those receiving chemotherapy alone (202/599; RR, 0.60; 95% CI, 0.45-0.79; Figure 2 ). In subgroup analysis, only the breast cancer patients had a significant benefit from the GnRHa therapy (RR, 0.57; 95% CI, 0.43-0.77), whereas no significant benefit was seen in the lymphoma patients (RR, 0.70; 95% CI, 0.20-2.47; Figure 2 ). In breast cancer patients, the hormonal receptor status did not influence the effect of GnRHa on the risk of POI (Figure 3 ), which was comparable among women with receptor positive (RR, 0.69; 95% CI, 0.48-1.00) Badawy (2009) 28 Elgindy (2013) 23 Gerber (2011) 29 Karimi-Zarchi (2014) 33 
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Demeestere (2016) 35 Giuseppe (2007) 24 Waxman (1987) 27 Subtotal (95% CI) Lambertini (2015) 25 Leonard (2017) 30 Moore (2015) 31 Munster (2012) 26 Song (2013) 34 Sverrisdottir (2009) and receptor negative (RR, 0.62; 95% CI, 0.33-1.14) tumors. When all patients were subdivided according to chemotherapy regimen into high toxicity vs low/medium toxicity 6 , the benefit of GnRHa therapy in preventing POI appeared to be of greater magnitude among women treated with low/medium toxicity chemotherapy (RR, 0.49; 95% CI, 0.29-0.84) compared with women treated with highly toxic chemotherapy (RR, 0.66; 95% CI, 0.45-0.96; Figure 4 ). The rate of spontaneous pregnancy after completion of treatment was higher in women receiving GnRHa plus chemotherapy (57/509) compared with those receiving chemotherapy alone (42/514; RR, 1.43; 95% CI, 1.01-2.02; Figure 5 ). However, this benefit was only seen for breast cancer patients (RR, 1.78; 95% CI, 1.09-2.90), not for lymphoma patients (RR, 1.13; 95% CI, 0.66-1.93). Only one study 31 reported the number of patients that were trying to conceive, which was 25 (24%) in the GnRHa plus chemotherapy group and 18 (6%) in the chemotherapy alone group. If these denominators were computed for the pregnancy rates, the overall benefit of GnRHa on this outcome would decrease and cross the significance threshold (RR, 1.29; 95% CI, 0.99-1.69). The impact of GnRHa therapy on the pregnancy rate did not differ between subgroups treated with chemotherapy regimens of low/medium vs high toxicity ( Figure S2 ).
Sensitivity analysis with study by study exclusion showed no significant changes in the RR for POI (Table S2 ). The lowest RR obtained was 0.57 (95% CI, 0.41-0.80) and the highest was 0.65 (95% CI, 0.51-0.83). The RR for spontaneous pregnancy increased to 1.62 (95% CI, 1.01-2.61) after excluding the largest lymphoma study 35 and decreased to 1.26 (95% CI, 0.84-1.89) after excluding one breast cancer study 31 (Table S2) .
Risk of bias
Although all 13 included studies were randomized, they were open-label. Therefore, we considered that all studies had unclear risks of performance bias (as the participants were not blinded) and detection bias (as the personnel 23 Gerber (2011) 29 Karimi-Zarchi (2014) 33 Lambertini (2015) 25 Lambertini (2015) 25 Moore (2015) 31 Munster (2012) 26 Munster (2012) 26 Song (2013) 34 Song (2013) were not blinded). This judgment was based on our perception that reporting on menstrual bleeding allows a large degree of subjectivity and imprecision 45 . Detection bias might arise if the personnel conducted follow-up surveys or interviews while knowing the patient study group, despite the relative 'objectivity' of the questions asked. Five studies had unclear risk of selection bias because the authors did not provide any information about the randomization process or the allocation concealment 24, 27, 29, 33, 34 . Four studies had a high proportion (more than 25%) of participants randomized but not included in the final analysis and were therefore rated as unclear risk of attrition bias [30] [31] [32] 35 . One study had high risk of attrition bias because the two groups differed significantly in their follow-up lengths 24 . In the final evaluation, 12 studies were considered to be at unclear risk of bias once they presented at least one unclear risk criterion and one study 24 was considered to be at high risk of bias ( Figure S1 ).
Funnel plot analysis did not show any asymmetry that might indicate a publication bias for the primary outcome, POI/amenorrhea, which was reported by all 13 studies included in the present review ( Figure 6 ). Because this analysis requires a minimum of 10 studies to be reliable 21 , it was not performed for subgroups or for outcomes reported in less than 10 studies.
Quality of evidence
Only low quality evidence was found supporting the use of GnRHa to prevent POI and increase pregnancy rates following chemotherapy (Table 1) . Even selecting only RCTs, the studies were seriously limited by their open-label design, which might have caused performance bias and/or detection bias. We also found serious indirectness for the POI outcome, as most studies used amenorrhea as a surrogate. The pregnancy outcome was evaluated with serious imprecision due to the small number of events. Overall, the quality of evidence was downgraded from high (the starting point of RCTs) to low, since each outcome had two serious reasons for uncertainty 22 . 28 Demeestere (2016) 35 Elgindy (2013) 23 Gerber (2011) 29 Karimi-Zarchi (2014) 33 Giuseppe (2007) 24 Low/medium toxicity High toxicity Waxman (1987) 27 Subtotal (95% CI) Lambertini (2015) 25 Leonard (2017) 30 Moore (2015) 31 Munster (2012) 26 Song (2013) Sverrisdottir (2009) increases the rate of spontaneous pregnancy. These benefits could be demonstrated only for patients with breast cancer, not for those with lymphoma. The protective effect of GnRHa was not dependent on the hormone receptor status in breast cancer patients.
DISCUSSION
Meta-analysis of the RCTs selected in this systematic
However, GnRHa appears to be more effective in low/medium toxicity than in high toxicity chemotherapy regimens. The reason for a weaker protection of GnRHa against highly toxic agents may be because these substances cause ovarian damage through multiple mechanisms beyond follicle destruction, such as cortical fibrosis, vascular lesions and accelerated atresia 6 . The most plausible mechanism of ovarian protection by GnRHa is the downregulation of pituitary GnRH receptors with drastic reduction of serum gonadotropin levels and blocking of follicular recruitment 46 . However, the main gonadotoxic effect of chemotherapy is on the resting primordial follicles 47 , which are responsible for ovarian reserve and do not respond to gonadotropins, casting doubt on how the suppression of pituitary gonadotropins would lead to any protection over the chemotherapy gonadotoxicity 48 . There is arguably a direct effect of GnRHa through the activation of ovarian GnRH receptors and release of antiapoptotic molecules 49 , which, however, has been refuted by a series of well-controlled in-vitro experiments with human ovarian tissue 50 . Despite the strict selection criteria, the studies included in the present meta-analysis have some important methodological differences. The GnRHa type, dose and route of administration varied largely across studies and no standard method was used to ascertain the timing and intensity of gonadotropin suppression by the GnRHa therapy. Breast cancer studies used many different combinations of cyclophosphamide, fluorouracil, doxorubicin, methotrexate, anthracyclines and taxanes. Considering the lymphoma studies, one study included high doses of chemotherapy for bone marrow transplantation 35 and another included treatment with supradiaphragmatic irradiation 24 . Nevertheless, the sensitivity analysis carried out by excluding each study did not change the results substantially. The discrepancy of results obtained for breast cancer and lymphoma patients may have many potential explanations, either biological 0.01
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Giuseppe (2007) 24 Waxman (1987) 27 Subtotal (95% CI) Subtotal (95% CI) Lambertini (2015) 25 Leonard (2017) 30 Moore (2015) 31 Munster (2012) (different age ranges, genetic backgrounds, chemotherapy agents) or methodological (small number of participants in the lymphoma studies, with insufficient statistical power). While some studies chose the absence of spontaneous menses as primary outcome [23] [24] [25] [26] [27] 29, 30, 32, 33 , others assessed POI by the presence of amenorrhea and altered FSH levels 28, 31, 34, 35 . However, residual ovarian function after chemotherapy has been demonstrated in patients with persistent amenorrhea 51 , while menstrual resumption post-treatment was not indicative of resumed ovulation 27 . As such, resumption of menses should not be trusted as an accurate marker of ovarian reserve 52, 53 .
Another possible source of heterogeneity and/or bias in the selected studies was the difference in follow-up length between groups 24 and between studies. Different follow-up times could impact on the chance of POI diagnosis, but also on the rates of menstrual cycle return and spontaneous pregnancy and thereby distort the results. As for the treatment schedule, only two studies 27, 34 reported waiting for the end of the flare-up effect of GnRHa, as verified by hormonal assays, before starting chemotherapy. One study 35 started the GnRHa treatment on average 3.8 days before chemotherapy, another 24 started GnRHa as soon as the cancer was diagnosed and a third study 23 Figure 6 Funnel plot of 13 studies included in systematic review and meta-analysis, analyzing the risk of primary ovarian insufficiency/amenorrhea in premenopausal women without prior diagnosis of infertility following treatment for breast cancer or lymphoma with gonadotropin-releasing hormone agonist (GnRHa) plus chemotherapy (CT) vs CT alone. OR, odds ratio.
antagonist cetrorelix for patients starting chemotherapy soon after the enrolment. The other studies started GnRHa 1-2 weeks before chemotherapy. Of the 13 included studies, only one reported the number of women attempting pregnancy and Table 1 Quality of evidence of 13 studies reporting on primary ovarian insufficiency (POI) and nine studies reporting on incidence of spontaneous pregnancy, in premenopausal women without prior diagnosis of infertility, following treatment for breast cancer or lymphoma with gonadotropin-releasing hormone agonist (GnRHa) plus chemotherapy (CT) vs CT alone However, GnRHa appears to be more effective in low-/medium-toxicity than in high-toxicity CT regimens.
Rate of spontaneous pregnancy after completion of treatment is higher in women receiving GnRHa + CT compared with those receiving CT alone. This benefit is not significant in lymphoma patients, but studies are few and small.
Quality of evidence Low Low *All studies were open-label, which might have caused performance bias and/or detection bias. †Some studies used amenorrhea as a surrogate for POI, while others confirmed the diagnosis with elevated follicle-stimulating hormone levels. ‡Open-label design might have increased number of women attempting to conceive in GnRHa group. §Seven studies estimated risk of pregnancy with large confidence intervals due to small number of events. RCT, randomized controlled trial; RR, relative risk.
calculated the pregnancy rate for this subgroup 31 . Furthermore, sample size calculation was not conducted in some studies 24, 27, 28, 32, 33 and, when calculated, the required number of participants was not reached in others 23, 25, 26, 29, 31, 35 . Previous systematic reviews with meta-analysis have addressed the effect of GnRHa on reproductive outcome of women with cancer undergoing chemotherapy, but their inclusion criteria differed from the present review as they included observational studies 12, 15 or were restricted to breast cancer [17] [18] [19] [20] [54] [55] [56] [57] . The conclusions of these previous reviews ranged from GnRHa having no significant impact on chemotherapy-induced amenorrhea 54 , to an association of GnRHa with lower risk of POI and higher pregnancy rate, suggesting that GnRHa 'might be considered as an option' for ovarian function preservation 57 . One previous systematic review included 10 RCTs published up to 2015 including a total of 907 participants with any type of cancer, and did not find a statistically significant benefit of GnRHa on the overall resumption of ovarian function 58 . However, in the present review, we included new studies 28, 30, 33, 34 and study updates 25, 35 , thereby increasing the sample size and narrowing the confidence intervals of our risk estimates.
Our results suggest that the prevention of POI in breast cancer patients is independent of the hormonal receptor status, whereas another meta-analysis limited to data published up to 2015 and using different inclusion criteria showed a protective effect of GnRHa only in patients not using tamoxifen (presumably with hormone insensitive tumors) 19 . In our opinion, only new RCTs stratifying patients by hormonal receptor status could clarify this question by minimizing confounding factors such as patient characteristics and treatment modalities, although it would remain a difficult task to separate the effects of using tamoxifen from those of having a hormone-sensitive tumor.
Although we found a statistically significant benefit of GnRHa for ovarian protection, particularly in women with breast cancer and/or receiving low/medium toxicity chemotherapy, we believe that the quality of the evidence is still insufficient to stop RCTs and recommend GnRHa therapy as a routine intervention in clinical practice. New RCTs with longer follow-up and periodic assessment of ovarian reserve, possibly double-blind but at least blinding the research personnel involved in outcome detection, such as sonologists/sonographers assessing ovarian follicle count, are needed to improve the strength of current evidence. The serial measurement of quantitative markers of ovarian reserve and function would provide more reproducible and relevant data to translate into clinical practice. The unexpected higher pregnancy rate in the controls in some studies 24, 27 suggests that larger samples and longer follow-up are needed to assess this outcome and its relation to the intervention.
In conclusion, low quality evidence supports the use of GnRHa before and/or during chemotherapy to reduce the risk of POI and increase the probability of spontaneous pregnancy in the short term. GnRHa should not replace proven techniques of fertility preservation, such as gamete and embryo vitrification, and should be regarded as an experimental intervention until high quality evidence is available to support definitive recommendations for clinical practice.
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